title: [5-FU based chemoradiotherapy for unresectable locally advanced pancreatic cancer].
abstract: Twenty-one patients with unresectable locally advanced pancreatic cancer were evaluated in this retrospective analysis. They received extra-beam radiotherapy(50.4-54 Gy/28-30 fractions)with concurrent continuous infusion of 5-FU(250 mg/m(2)day)between December 1999 and April 2007. The radiation field included primary tumor and adjacent lymph nodes. Twenty patients(95%)completed chemoradiotherapy, although one patient quit radiotherapy due to vomiting. No lethal side effects were observed. The response rate was 10%. One of the patients judged to have stable disease underwent resection after maintenance chemotherapy. The median progression free survival and the median overall survival were 6.4 and 12 months, respectively. In eleven patients(52%), the initial sites of disease progression were local or peritoneum without liver metastases, suggesting systemic effects of this treatment. In conclusion, 5-FU based chemoradiotherapyis well tolerated and provides definite benefits against unresectable locally advanced pancreatic cancer.
authors.affiliation: Dept. of Gastrointestinal and Hepatobiliary Oncology, Hyogo Cancer Center, Japan.
authors.forename: Toshiharu
authors.initials: T
authors.lastname: Niki
authors.forename: Toshinori
authors.initials: T
authors.lastname: Soejima
authors.forename: Takurou
authors.initials: T
authors.lastname: Yoshikawa
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: Osamu
authors.initials: O
authors.lastname: Fujii
authors.forename: Yousuke
authors.initials: Y
authors.lastname: Ohta
authors.forename: Masahiro
authors.initials: M
authors.lastname: Tsuda
authors.forename: Kazutsugu
authors.initials: K
authors.lastname: Horita
authors.forename: Kayoko
authors.initials: K
authors.lastname: Tsujino
authors.forename: Shigeya
authors.initials: S
authors.lastname: Hirohata
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Fujino
authors.forename: Hogara
authors.initials: H
authors.lastname: Nishisaki
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018450:Disease Progression; D004307:Dose-Response Relationship, Radiation; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D005472:Fluorouracil